# TOMI Environmental Solutions, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/TOMI Environmental Solutions, Inc.). ## Overview TOMI Environmental Solutions, Inc. develops and commercializes disinfection and decontamination technologies for use in controlled environments and public spaces. Its business centers on hydrogen peroxide-based systems and related application methods sold into healthcare, life sciences, food safety, and other contamination-sensitive settings in the United States and international markets. ## Products & services • SteraMist disinfection systems • Binary Ionization Technology (BIT) • Surface and room decontamination services • Fogging and spray application solutions • Consumables and service support - **Disinfection systems** (45%) — Equipment and systems used to apply TOMI's disinfection technology in rooms, surfaces, and enclosed spaces. - **Consumables and accessories** (20%) — Replacement parts, consumables, and application components used with installed systems. - **Service and decontamination work** (25%) — Direct disinfection, decontamination, and application services performed for customers. - **Licensing and other revenue** (10%) — Other commercial arrangements tied to the company's proprietary technology and related offerings. - SteraMist disinfection systems - Binary Ionization Technology (BIT) - Surface and room decontamination services - Fogging and spray application solutions - Consumables and service support ## Customers TOMI sells to organizations that need validated disinfection and contamination control, especially where hygiene standards are critical. Typical buyers include hospitals, laboratories, pharmaceutical and biotech facilities, food processing operators, and commercial or institutional users that need repeatable room and surface treatment. - **Healthcare** (primary) — Hospitals and clinical facilities buy disinfection systems and services for patient rooms, equipment, and high-touch areas. - **Life sciences and laboratories** (primary) — Labs and research facilities use the technology to reduce contamination risk in controlled environments. - **Pharmaceutical and biotech** (secondary) — Manufacturers and cleanroom operators buy decontamination solutions to support sterile operations. - **Food and beverage** (secondary) — Processors and related facilities use sanitation solutions to support hygiene and compliance. - **Commercial and institutional** (emerging) — Schools, offices, transportation, and other public venues may purchase disinfection systems or services. - Hospitals and healthcare facilities needing room disinfection - Life sciences and laboratory users controlling contamination - Pharmaceutical and biotech sites with clean-environment needs - Food safety customers requiring sanitation protocols - Commercial and institutional buyers seeking surface decontamination ## Geography The company is based in the United States and serves domestic customers as well as international markets through commercial sales and distribution relationships. Geography matters because adoption of disinfection technology depends on local regulatory standards, customer budgets, and the presence of healthcare and industrial end markets. - United States is the core operating and customer base - International sales expand the addressable market for SteraMist - Healthcare and lab density influences regional demand - Distribution and service reach affect adoption outside the U.S. ## Strategy TOMI's strategy is centered on commercializing its proprietary disinfection platform across regulated and contamination-sensitive end markets. The company relies on expanding installed usage, broadening customer adoption, and supporting recurring demand through consumables, service work, and application support. - **Commercialize proprietary disinfection technology** (short-term) — A differentiated technology platform can support customer adoption and pricing power versus commodity cleaning products. - **Increase recurring revenue mix** (medium-term) — Consumables and service work can create repeat demand after initial system placement. - **Expand into regulated end markets** (medium-term) — Healthcare, labs, and pharma customers have persistent contamination-control needs and higher switching costs. - Expand adoption of SteraMist across healthcare and life sciences - Grow recurring consumables and service revenue around installed systems - Use proprietary BIT technology to differentiate from generic disinfectants - Broaden distribution and customer reach beyond the U.S. - Target contamination-sensitive end markets with repeat-use demand ## Risks TOMI depends on customer adoption of a specialized technology platform, so demand can be uneven and tied to capital spending cycles in healthcare and industrial end markets. The company also faces execution risk in scaling sales, supporting installations, and converting interest in disinfection technology into repeatable revenue, while broader risks include competition from alternative sanitation methods and regulatory or validation requirements. - **Customer adoption and demand variability** [high] — The business depends on customers choosing a specialized disinfection platform rather than standard cleaning or competing technologies. - **Competitive substitution** [medium] — Alternative disinfectants, UV systems, and contract cleaning providers can reduce demand for TOMI's systems and services. - **Regulatory and validation burden** [medium] — Customers in regulated environments often require proof of efficacy and compliance before adoption. - **Small-company execution risk** [high] — A niche commercial model requires effective sales, installation, and service execution to convert pipeline into revenue. - Customer adoption risk if buyers choose lower-cost alternatives - Sales concentration risk in healthcare and contamination-sensitive markets - Execution risk in scaling installations and service support - Regulatory and validation requirements can slow customer adoption - Competition from chemical, UV, and other disinfection methods ## Accounting For investors, the key accounting issues are revenue timing, especially where the company sells equipment, consumables, and services with different recognition patterns. Because the business can include product sales, service work, and financing-like instruments, judgment around collectability, contract terms, and any embedded conversion features can materially affect reported results. - **Revenue recognition by product and service type** — Reported revenue mix and timing - **Convertible promissory notes** — Debt balance, interest expense, and potential dilution - **Allowance for doubtful accounts** — Net revenue and receivables - **Inventory and equipment valuation** — Gross margin and asset values - Revenue recognition differs for equipment, consumables, and services - Private placement notes may require debt and derivative assessment - Collectability and customer credit risk can affect revenue and reserves - Inventory and equipment valuation matter for a small product business - Convertible note terms can create fair value and dilution complexity --- *Last updated: 2026-04-29T05:02:12.822530+00:00*